Moran, J.; Mylod, E.; Kane, L.E.; Marion, C.; Keenan, E.; Mekhaeil, M.; Lysaght, J.; Dev, K.K.; O’Sullivan, J.; Conroy, M.J.
Investigating the Effects of Olaparib on the Susceptibility of Glioblastoma Multiforme Tumour Cells to Natural Killer Cell-Mediated Responses. Pharmaceutics 2023, 15, 360.
https://doi.org/10.3390/pharmaceutics15020360
AMA Style
Moran J, Mylod E, Kane LE, Marion C, Keenan E, Mekhaeil M, Lysaght J, Dev KK, O’Sullivan J, Conroy MJ.
Investigating the Effects of Olaparib on the Susceptibility of Glioblastoma Multiforme Tumour Cells to Natural Killer Cell-Mediated Responses. Pharmaceutics. 2023; 15(2):360.
https://doi.org/10.3390/pharmaceutics15020360
Chicago/Turabian Style
Moran, Jennifer, Eimear Mylod, Laura E. Kane, Caroline Marion, Emily Keenan, Marianna Mekhaeil, Joanne Lysaght, Kumlesh K. Dev, Jacintha O’Sullivan, and Melissa J. Conroy.
2023. "Investigating the Effects of Olaparib on the Susceptibility of Glioblastoma Multiforme Tumour Cells to Natural Killer Cell-Mediated Responses" Pharmaceutics 15, no. 2: 360.
https://doi.org/10.3390/pharmaceutics15020360
APA Style
Moran, J., Mylod, E., Kane, L. E., Marion, C., Keenan, E., Mekhaeil, M., Lysaght, J., Dev, K. K., O’Sullivan, J., & Conroy, M. J.
(2023). Investigating the Effects of Olaparib on the Susceptibility of Glioblastoma Multiforme Tumour Cells to Natural Killer Cell-Mediated Responses. Pharmaceutics, 15(2), 360.
https://doi.org/10.3390/pharmaceutics15020360